IMUX Immunic Inc

$IMUX I’ve made and lost thousands in biotech over the last 7 years, the last clinical stage one I owned didn’t impress in Phase 2B and went under, lost me $55,000. this is the only bio left that I own, although not as big of a position this time. This will probably be my last go at these high risk companies as I just found out I have baby on the way! I really like the potential here, my average $10.66 and I’m still adding a bit more for the next few weeks, good luck to everyone. If successful I think it’s worth $50-$100 minimum.

$IMUX I’ll admit it. I’m nearly all in here with 30k shares and have lost almost $400K paper in just under 6 weeks Most I’ve ever dropped in a short period Need to get that off the chest Good luck to us as we need it

Latest company news, October 19, 2026: Immunic appointed Jaa Roberson as Chief People Officer, a newly created role, ahead of the pivotal Phase 3 ENSURE read-out expected by the end of 2026. Immunic $IMUX Stock Hub Not investment advice. More details in our stock hub.

$IMUX it appears to be trading lower than cash value. Data coming, 100% buy by analysts. Added below 8. Let's moon 🚀

$IMUX I've seen this story play out a million times. And the next thing you're telling yourself is damn it why didn't I buy when it was down that low

$IMUX estimated data release? Didn’t they already have positive data before phase 3. Looking good to buy I think

$IMUX reminder for my fellow longs - price doesn’t matter until phase 3 results are out. $100 or $0 after that. $8 or $16 doesn’t matter!

$IMUX Poster Title: Evaluation of Disability Outcomes from the Open-Label Extension of CALLIPER: A Phase 2 Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Poster Title: Vidofludimus Calcium Requires Nurr1 to Promote Neuronal Survival In Vitro and Is Associated with Neuroprotective Effects in Murine Models of Multiple Sclerosis Poster Title: Anti-EBV T-cell Receptor Repertoire Reduction Is Linked to Enhanced Cognitive Performance in Progressive Multiple Sclerosis: Evidence from the Phase 2 CALLIPER Trial with Vidofludimus Calcium, a Direct Nurr1 Activator and Selective DHODH Inhibitor Poster Title: Bidirectional Disability Changes in Progressive Multiple Sclerosis Patients: a Proposed Endpoint to Capture Full Treatment Effects

$IMUX Absolutely stomach churning. My paper clip collection has a larger market cap now.

$IMUX wtf! The company has $160M in assets and $32M in liabilities. i.e. The shareholders value is $132M. The outstanding number of shares is 13.64M. This means $9.67 per share yet the share price is at $6.89 trading below the book value at 71% from the book value. crazy

$IMUX I’m not selling. Going to fluctuate until phase 3 results announced. If in line with phase 2, we will see a considerable pop IMO, as fda approval will be very likely. I’ve been in IOVA for a while and watched MM’s short it to hell, choose to add throughout the drop and glad I did. Hoping IMUX will be similar

$IMUX What the actual fuck...down 12% on nothing - unless there IS something we don't know about.

$IMUX for all the red days, following the readout coming here soon I hope this thing really pops

$IMUX Immunic to present new clinical, biomarker and preclinical data on Vidofludimus Calcium at MSToronto2026

$IMUX I should have known this would drop today, because I bought some more shares yesterday. Like I needed a reason to pop a top. Enjoy the weekend all. Cheers-

$IMUX next week additional data for remibrutinib , if Novartis data is excellent as before and we can’t beat that with vidu (eoy) we loose the RMS market. Hopefully we raise the bar.

$IMUX I have contacted the analyst at Wedbush Securities who has $45 target price on tge stock and asked about the recent price action and here is his response "Our view on recent price action is the stock has been under pressure since NVS announced plans to disclose remibrutinib data at MSToronto, and that IMUX will remain under pressure until NVS’s data event scheduled for Friday, Oct. 23." I have sold my 1799 shares this morning for a loss and I will stay on the sidelines until 10/23/2026 at least. GLTA

$IMUX I’ll admit it, I’ve been secretly hoping this would dip for my next buy before things heat up.

$IMUX Stay patient…this is lulling you to sleep (miserable sleep), but this is a powder keg with data. And no one knows the results…last patient in this month. This slide is biotech selloff plus warrant holders taking some off the table. And NOTE: If this is warrant selling since September, you will see substantial new capital raised…the warrant holders are REQUIRED to excercise their common warrant first (and therefore buy for full stock price)…if they don’t and exceexise their pre funded warrant first (which gives no cash to IMUX) they FORFEIT their common warrant (and they won’t do that). So dilution is happening earlier than the data release…so a steeper slide in the stock given the market wasn’t anticipating the common warrants being exercised/issued before data (only the pre-funded warrants) —so it’s like getting dilution before we know the data. Could be a gift to buyers right now!

$IMUX Welp, at least we’re nowhere near the support at 6.9! Stay optimistic! lol Data is all that matters now.